Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments

Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas 10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp WESTLAKE VILLAGE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that six-time PGA Tour winner Max Homa has joined the company's Free to Be Me awareness campaign to help encourage the millions of Americans living with seborrheic dermatitis (seb derm) to speak with their healthcare providers about long-term treatment options.

GlobeNewsWire • 13 hours ago

Arcutis After The Double: Hypergrowth Peaks, Compounding Remains

Arcutis Biotherapeutics shifts to Hold after a 100% rally, as much of the initial de-risked growth thesis has played out. ZORYVE approvals and revenue growth have driven a fair rerating, but forward expectations now imply slower compounding and less favorable risk/reward. ARQT's long-term upside remains via steroid market conversion and pipeline optionality, yet near-term catalysts are limited and growth deceleration is expected.

Seeking Alpha • Feb 20, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy?

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 18, 2026

This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit

Tejara Capital sold 520,503 shares of Arcutis Biotherapeutics in the fourth quarter. The quarter-end position value decreased by $9.81 million, reflecting the full exit and price changes.

The Motley Fool • Feb 6, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,000 restricted stock units of Arcutis' common stock to 12 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of February 2, 2026, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Feb 5, 2026

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

WESTLAKE VILLAGE, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced positive topline results from the INTEGUMENT-INFANT Phase 2 study evaluating the safety, tolerability, and efficacy of ZORYVE® (roflumilast) cream 0.05% in infants aged 3 months to less than 24 months with atopic dermatitis. ZORYVE cream, a highly selective and potent topical phosphodiesterase 4 (PDE4) inhibitor, was well tolerated with a safety profile consistent with previous ZORYVE clinical trials. Overall, the incidence of adverse events was low, with all being mild to moderate in severity. ZORYVE cream improved the severity of disease and reduced the area of skin affected by atopic dermatitis, with 58% of participants achieving EASI-75 at Week 4.

GlobeNewsWire • Feb 2, 2026

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa

WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America, Inc. mutually agreed to terminate their promotion agreement. The agreement covered sales and promotion of ZORYVE® (roflumilast) by Kowa to primary care physicians and pediatricians in the United States.

GlobeNewsWire • Jan 26, 2026

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.

GlobeNewsWire • Jan 22, 2026

Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 adults and parents agreed that their or their child's treatment plan focuses on reactively “taming a flare” rather than proactive long-term solutions When their skin condition is uncontrolled, nearly all adults and children experience emotional, mental, and daily life challenges WESTLAKE VILLAGE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced results of Skin Insights: Steroid Perceptions in Chronic Inflammatory Skin Diseases, a nationwide survey of adults and parents of children with plaque psoriasis, atopic dermatitis (the most common form of eczema), and seborrheic dermatitis.

GlobeNewsWire • Jan 21, 2026

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 million Advancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis suppurativa Initiation of clinical development program for ARQ-234 in atopic dermatitis Transition to positive cash flows enables investment to both accelerate growth of ZORYVE franchise and advance pipeline WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced its strategic priorities for 2026.

GlobeNewsWire • Jan 12, 2026